Change in Weight From Baseline Across Doses (lb)1
Panel of 5 lollipop graphs showing the mean change in weight in the SURPASS 1-5 studies. The first graph shows Mounjaro vs placebo as monotherapy. From a mean baseline weight of 191.8 lb (Mounjaro 5 mg, n=121), 190.0 lb (Mounjaro 10 mg, n=121), 188.5 lb (Mounjaro 15 mg, n=120), and 186.3 lb (placebo, n=113), mean change in weight at 40 weeks was -14 lb, -15 lb, -17 lb, and -2 lb, respectively. The second graph shows Mounjaro vs Ozempic 1 mg as add-on to metformin. From a mean baseline weight of 203.9 lb (Mounjaro 5 mg, n=470), 209.0 lb (Mounjaro 10 mg, n=469), 206.8 lb (Mounjaro 15 mg, n=469), and 206.6 lb (Ozempic 1 mg, n=468), mean change in weight at 40 weeks was -17 lb, -21 lb, -25 lb, and -13 lb respectively. The third graph shows Mounjaro vs Tresiba as add-on to metformin with or without SGLT2i. From a mean baseline weight of 208.1 lb (Mounjaro 5 mg, n=358); 206.8 lb (Mounjaro 10 mg, n=360); 209.2 lb (Mounjaro 15 mg, n=358), and 207.2 lb (Tresiba, n=359), mean change in weight at 52 weeks was -15 lb, -21 lb, -25 lb, and +4 lb, respectively. The fourth graph shows Mounjaro vs insulin glargine as add-on to 1-3 oral antihyperglycemic medications (metformin, SGLT2i, or sulfonylurea). From a mean baseline weight of 199.1 lb (Mounjaro 5 mg, n=328), 199.7 lb (Mounjaro 10 mg, n=326), 198.4 lb (Mounjaro 15 mg, n=337), and 198.9 lb (insulin glargine, n=998), mean change in weight at 52 weeks was -14 lb, -20 lb, -23 lb, and +4 lb, respectively. The fifth graph shows Mounjaro vs placebo as add on to basal insulin with or without metformin. From a mean baseline weight of 211.2 lb (Mounjaro 5 mg, n=116), 208.6 lb (Mounjaro 10 mg, n=118), 211.6 lb (Mounjaro 15 mg, n=118), and 207.7 lb (placebo, n=119), mean change in weight at 40 weeks was -12 lb, -17 lb, -19 lb, and +4 lb, respectively.